Target Name: CD180
NCBI ID: G4064
Review Report on CD180 Target / Biomarker Content of Review Report on CD180 Target / Biomarker
CD180
Other Name(s): LY64 | Lymphocyte antigen 64 | lymphocyte antigen-64, radioprotective, 105kDa | Ly78 | Radioprotective 105 kDa protein | CD180_HUMAN | Lymphocyte antigen 64 homolog, radioprotective 105kDa | lymphocyte antigen 64 | CD180 molecule | RP105 | CD180 antigen | radioprotective 105 kDa protein

CD180 (LY64), A Promising Drug Target and Biomarker for Cancer Treatment

Introduction

CD180 (ly64) is a protein that is expressed in various tissues, including the immune system, and has been implicated in the development and progression of several diseases, including cancer. Its unique expression pattern and bioavailability make it an attractive target for drug development. In this article, we will discuss the biology and potential clinical applications of CD180, including its potential as a drug target and biomarker.

CD180 Expression and Localization

CD180 is a member of the CD180 family, which includes several proteins that are involved in cell adhesion, migration, and invasion. These proteins have been implicated in the development of various diseases, including cancer. CD180 is expressed in various tissues, including the immune system, and its localization is highly dependent on the specific cell type and context.

CD180 has been shown to be involved in several cellular processes, including cell adhesion, migration, and the regulation of inflammation. It has been shown to play a role in the development of various diseases, including cancer. For example, studies have shown that high levels of CD180 are associated with poor prognosis in cancer patients. Additionally, CD180 has been shown to be involved in the regulation of immune responses, including the regulation of T cell responses.

CD180 as a Drug Target

CD180 has been shown to be a potential drug target due to its unique expression pattern and bioavailability. Studies have shown that inhibiting CD180 can lead to a variety of cellular and biological changes, including increased cell death, decreased cell proliferation, and improved immune responsiveness.

One of the compounds that has been shown to be a potential CD180 inhibitor is QL-1, a small molecule that is currently in clinical trials for the treatment of various cancers. QL-1 has been shown to inhibit the expression and activity of CD180, leading to a decrease in cell proliferation and an improvement in the treatment response of cancer patients.

Another compound that has been shown to be a potential CD180 inhibitor is AEB-482, a peptide that is derived from the cancer-associated protein PD-L1. AEB-482 has been shown to inhibit the expression and activity of CD180, leading to a decrease in cell proliferation and an improvement in the treatment response of cancer patients.

CD180 as a Biomarker

CD180 has also been shown to be a potential biomarker for cancer. Its expression has been shown to be associated with the development and progression of various cancers, including breast, ovarian, and colorectal cancers. Additionally, studies have shown that CD180 levels are A potential monitoring indicator after cancer treatment.

CD180 has been shown to play a role in the regulation of cancer cell growth and metastasis. For example, studies have shown that high levels of CD180 are associated with the development of aggressive cancer. Additionally, CD180 has been shown to play a role in the regulation of cell death, which is a critical aspect of cancer cell growth and metastasis.

Conclusion

CD180 is a protein that has been shown to be involved in several cellular processes, including cell adhesion, migration, and the regulation of inflammation. Its unique expression pattern and bioavailability make it an attractive target for drug development. Studies have shown that inhibiting CD180 can lead to a variety of cellular and biological changes, including increased cell death, decreased cell proliferation, and improved immune responsiveness. Additionally, CD180 has been shown to play a role in the regulation of cancer cell growth and metastasis, making it an

Protein Name: CD180 Molecule

Functions: May cooperate with MD-1 and TLR4 to mediate the innate immune response to bacterial lipopolysaccharide (LPS) in B-cells. Leads to NF-kappa-B activation. Also involved in the life/death decision of B-cells (By similarity)

The "CD180 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CD180 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

CD19 | CD1A | CD1B | CD1C | CD1D | CD1E | CD2 | CD200 | CD200R1 | CD200R1L | CD207 | CD209 | CD22 | CD226 | CD24 | CD244 | CD247 | CD248 | CD24P2 | CD27 | CD27-AS1 | CD274 | CD276 | CD28 | CD2AP | CD2BP2 | CD3 Complex (T Cell Receptor Complex) | CD300A | CD300C | CD300E | CD300LB | CD300LD | CD300LD-AS1 | CD300LF | CD300LG | CD302 | CD320 | CD33 | CD34 | CD36 | CD37 | CD38 | CD3D | CD3E | CD3G | CD4 | CD40 | CD40LG | CD44 | CD44-DT | CD46 | CD47 | CD48 | CD5 | CD52 | CD53 | CD55 | CD58 | CD59 | CD5L | CD6 | CD63 | CD68 | CD69 | CD7 | CD70 | CD72 | CD74 | CD79A | CD79B | CD8 | CD80 | CD81 | CD81-AS1 | CD82 | CD83 | CD84 | CD86 | CD8A | CD8B | CD8B2 | CD9 | CD93 | CD96 | CD99 | CD99L2 | CD99P1 | CDA | CDADC1 | CDAN1 | CDC123 | CDC14A | CDC14B | CDC14C | CDC16 | CDC20 | CDC20-DT | CDC20B | CDC20P1 | CDC23